{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:10:36Z","timestamp":1778076636492,"version":"3.51.4"},"posted":{"date-parts":[[2026,5,6]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,17]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background<\/bold>\n                  Impaired glymphatic clearance has been implicated in Alzheimer\u2019s disease (AD) through reduced clearance of amyloid-\u03b2 (A\u03b2) and other metabolites from the brain. Mislocalisation of aquaporin-4 (AQP4), a water channel protein anchored to astrocytic endfeet by the dystrophin-associated complex (DAC), has been linked to increased A\u03b2 accumulation, neurodegeneration and cognitive impairment. In animal models, genetic ablation of DAC subunits, leading to AQP4 mislocalisation, increases A\u03b2 accumulation. Genetic variation in\n                  <italic>AQP4<\/italic>\n                  has been examined in the context of AD, but variation in key DAC genes has not been systematically investigated in humans. This study examined whether variation within glymphatic pathway genes is associated with AD-related phenotypes in individuals on the AD trajectory.\n                  <bold>Methods<\/bold>\n                  Associations between genetic variation in glymphatic pathway-related genes (\n                  <italic>AQP4<\/italic>\n                  and three DAC genes:\n                  <italic>DAG1<\/italic>\n                  ,\n                  <italic>DTNA<\/italic>\n                  , and\n                  <italic>SNTA1<\/italic>\n                  ) and brain A\u03b2 burden, cognition and regional brain volumes were analysed in two longitudinal cohorts of cognitively unimpaired older adults who were A\u03b2-positive or demonstrated ongoing A\u03b2 accumulation. Linear regression models assessed cross-sectional and longitudinal outcomes within each cohort, followed by a meta-analysis. Pathway-based glymphatic genetic risk scores (G-GRS) were constructed to assess cumulative genetic impact.\n                  <bold>Results<\/bold>\n                  At the single-variant level,\n                  <italic>AQP4<\/italic>\n                  ,\n                  <italic>DTNA<\/italic>\n                  , and\n                  <italic>DAG1<\/italic>\n                  showed significant associations with cognition, grey matter atrophy, and ventricular volume after correction for multiple testing. Variants in\n                  <italic>AQP4<\/italic>\n                  (rs10502478 and rs10164026) were associated with differences in cross-sectional PACC scores. Whilst rs45556134 within\n                  <italic>DTNA<\/italic>\n                  was associated with grey matter atrophy. Further, six variants (rs13079082\n                  <italic>DAG1<\/italic>\n                  , rs8092794, rs17642885, rs7233779, rs78837792 and rs79500711\n                  <italic>DTNA<\/italic>\n                  ) were associated with cross-sectional ventricular volumes. At the polygenic level, higher G-GRS were associated with lower grey matter volume, faster grey matter atrophy, larger ventricular volumes and lower cognitive composite scores.\n                  <bold>Conclusions<\/bold>\n                  Variation within key glymphatic pathway genes is associated with early differences in cognition and neurodegeneration-related brain measures in cognitively unimpaired A\u03b2-positive older adults. These findings support a contributory role for glymphatic pathway dysfunction in early AD-related brain vulnerability and identify glymphatic pathway genetic risk as a potential marker for risk stratification. A limitation of this study is the absence of direct experimental measures of glymphatic clearance function, which will be required to confirm the functional impact of these genetic findings.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9444687\/v1","type":"posted-content","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:12:29Z","timestamp":1778073149000},"source":"Crossref","is-referenced-by-count":0,"title":["Genetic variation in the glymphatic pathway predicts cognition and neurodegeneration in preclinical Alzheimer's disease"],"prefix":"10.21203","author":[{"given":"Ayeisha Milligan","family":"Armstrong","sequence":"first","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor K.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane M.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrick","family":"Bourgeat","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosita","family":"Shishegar","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[{"name":"Cogstate (Australia)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Austin Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"the Alzheimer\u2019s Disease Neuroimaging","family":"Initiative","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"the AIBL Research","family":"Group","sequence":"additional","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenielle","family":"Porter","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon M.","family":"Laws","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9444687\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9444687\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:12:29Z","timestamp":1778073149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9444687\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9444687\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,5,6]]},"subtype":"preprint"}}